Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S ADR
(NQ:
GMAB
)
28.38
+0.25 (+0.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Genmab A/S ADR
< Previous
1
2
3
4
5
6
Next >
Investors seeking growth at a reasonable cost should explore NASDAQ:GMAB.
January 18, 2024
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via
Chartmill
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.
December 26, 2023
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Via
Chartmill
Oracle Reports Weak Sales, Joins Kinetik, Lucid Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
December 12, 2023
U.S. stock futures were higher this morning, with the Dow Jones futures gaining over 50 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
In the world of growth stocks, NASDAQ:GMAB shines as a value proposition.
December 05, 2023
Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB).
Via
Chartmill
9 Analysts Have This to Say About Genmab
November 28, 2023
Via
Benzinga
7 Must-Buy Stocks That Are on Ridiculous Discount Now
November 13, 2023
With Wall Street still chasing after the usual suspects in the tech ecosystem, astute investors may wish to target stocks on sale.
Via
InvestorPlace
NASDAQ:GMAB is not too expensive for the growth it is showing.
November 10, 2023
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
Via
Chartmill
Analyst Expectations for Genmab's Future
November 08, 2023
Via
Benzinga
NASDAQ:GMAB, a strong growth stock, setting up for a breakout.
November 01, 2023
GENMAB A/S -SP ADR (NASDAQ:GMAB)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via
Chartmill
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
November 09, 2023
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
October 20, 2023
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.
Via
Chartmill
United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 18, 2023
U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
What 13 Analyst Ratings Have To Say About Genmab
October 13, 2023
Via
Benzinga
Expert Ratings for Genmab
September 26, 2023
Via
Benzinga
Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher
September 26, 2023
With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio.
Via
InvestorPlace
Analyst Expectations for Genmab's Future
September 05, 2023
Via
Benzinga
Analyst Expectations for Genmab's Future
August 15, 2023
Via
Benzinga
12 Analysts Have This to Say About Genmab
July 24, 2023
Via
Benzinga
Why Shares of Iovance Biotherapeutics Dropped Thursday
September 14, 2023
The biotech stock's lead therapy is looking at some competition.
Via
The Motley Fool
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
September 11, 2023
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients
Via
Benzinga
Why Shares of Zai Lab Limited Were Jumping on Tuesday
September 05, 2023
Zai Lab's shares benefited from positive clinical trial news.
Via
The Motley Fool
Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications
September 05, 2023
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on...
Via
Benzinga
The 3 Most Promising Biotech Stocks to Own Now
August 31, 2023
These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023
August 24, 2023
Via
Benzinga
Is AbbVie Still a Good Dividend Stock to Buy?
August 08, 2023
Find out if AbbVie can overcome sinking sales of its top-selling product.
Via
The Motley Fool
3 Things About Johnson & Johnson Every Smart Investor Knows
July 28, 2023
The company has been a strong value stock but faces big changes this year.
Via
The Motley Fool
3 Biotech Stocks You Better Be Buying on Each and Every Dip
July 27, 2023
Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there.
Via
InvestorPlace
3 Biotech Stocks That AI is Loving in July
July 12, 2023
As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential.
Via
InvestorPlace
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
July 02, 2023
In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.
Via
The Motley Fool
Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients
June 28, 2023
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) have announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.